Barriers to Entry and Barriers to Validation

(See the slides here)

In the final section of my recent keynote address for Cancer Research UK‘s 2019 Symposium on Oesophageal Cancer, I departed from my usual rants on technical rigor in science to discuss the political barriers that keep us from effectively translating and scaling new diagnostics in …

Interactive Preference Ranking

It’s not always easy to figure out the relative importance of our various preferences. For example, when trying to find a place to move, do you care more about price, walkability, parking, proximity to work, safety, …? Or when trying to find a job, is it about salary, equity, the …

Three Principles for AI/ML in Drug Discovery

(See the slides here)

I was recently invited by OpenEye Scientific to speak at their 19th CUP meeting - a scientific conference focused on challenges of computational modeling in drug discovery. It was my first time back at CUP in 8 years, since I switched fields from computational chemistry into computational …

The Drug Discovery Checklist

Drug discovery is a hard business, and like any other hard business, there are a lot of people who’d not only like to improve it, but think they have a clever idea to completely change how it’s done and catapult us into a new world of productivity. It …

Six interesting abstracts from ASCO GI 2019

I saw a billboard for a Very Well Known cancer drug on US101 today and realized that ASCO’s Gastrointestinal Cancers Symposium (aka ASCO GI) was in town. Although I’m not currently working on CRC screening, it’s an interesting enough area for me to have spent a couple …